Pars plana vitrectomy combined with pan-retinal photocoagulation, Ahmed glaucoma valve implantation, and/or phacoemulsification for complicated neovascular glaucoma treatment / Vitrectomia pars plana combinada com fotocoagulação panretiniana, implantação da válvula Ahmed para glaucoma e/ou facoemulsificação para tratamento de glaucoma neovascular complicado

ABSTRACT Purpose: To present long-term results of pars plana vitrectomy combined with pan-retinal endolaser photocoagulation, Ahmed glaucoma valve implantation, and/or phacoemulsification in patients with complicated neovascular glaucoma. Methods: The study comprised 15 eyes from 15 patients with neovascular glaucoma as a complication of diabetic retinopathy and owing to ischemic central retinal vein occlusion. There was a vitreous hemorrhage n all of the patients. Furthermore, 8 of the cases showed varying degrees of hyphema. All subjects received an intravitreal injection of bevacizumab three days before surgery. In 12 phakic patients, phacoemulsification, pars plana vitrectomy, and Ahmed glaucoma valve implantation were performed. Pars plana vitrectomy and Ahmed glaucoma valve implantation were performed in 3 pseudophakic patients. Perioperative and postoperative complications, intraocular pressure values, and best-corrected visual acuity scores were also recorded. Results: The mean follow-up was 24.4 ± 14.56 months. The mean preoperative intraocular pressure was 50.06 ± 7.6 mmHg. At 1 day, 7 days, and 1-, 3-, 6-, 12-month, and last visit following surgery, the mean intraocular pressure was 11.06 ± 8.22, 12.66 ± 7.27, 13.8 ± 7.73, 18.64 ± 7.05, 19.28 ± 4.61, 16.28 ± 1.68, and 16.92 ± 2.12 mmHg, respectively (p=0.001 for every follow-up visit). The mean visual acuity on the most recent appointment was 1.18 ± 0.42 logMar (p=0.001 for each subsequent visit). As postoperative early complications, varying degrees of hyphema and fibrin reactions were recorded. During follow-up, one patient developed phthisis bulbi. In 4 cases, Ahmed glaucoma valve revision surgery was required. Conclusions: In patients with complicated neovascular glaucoma, combined surgical procedures are safe, effective, and preferable both in terms of controlling high intraocular pressure and providing reasonable visual abilities.

RESUMO Objetivo: Apresentar nossos resultados de longo período de vitrectomia pars plana combinada com fotocoagulação panretiniana com endolaser, implantação da válvula Ahmed para glaucoma e/ou facoemulsificação em pacientes com glaucoma neovascular complicado. Métodos: Foram incluídos no estudo 15 olhos de 15 pacientes com glaucoma neovascular como complicação da retinopatia diabética e devido à oclusão isquêmica da veia central da retina. Todos os casos tiveram hemorragia vítrea. Além disso, 8 dos casos apresentaram diferentes graus de hifema. A injeção intravítrea de bevacizumabe foi administrada em todos os casos 3 dias antes da cirurgia. Facoemulsificação, vitrectomia pars plana e implantação da válvula Ahmed para glaucoma foram realizadas em 12 pacientes fáquicos. A vitrectomia pars plana e a implantação da válvula Ahmed para glaucoma foram realizadas em 3 pacientes pseudofáquicos. Complicações perioperatórias e pós-operatórias, valores de pressão intraocular e valores de melhor acuidade visual corrigida pré-operatório e pós-operatório foram registrados. Resultados: O acompanhamento médio foi de 24,4 ± 14,56 meses. A média da pressão intraocular pré-operatória foi de 50,06 ± 7,6 mmHg. Em 1 dia, 7 dias e 1,3,6,12 meses, e última visita após cirurgia, a média da pressão intraocular foi de 11,06 ± 8,22, 12,66 ± 7,27, 13,8 ± 7,73, 18,64 ± 7,05, 19,28 ± 4,61, 16,28 ± 1,68 e 16,92 ± 2,12 mmHg, respectivamente (p=0,001 para cada visita de acompanhamento). A média da acuidade visual na última visita foi de 1,18 ± 0,42 logMar (p=0,001 para cada visita de acompanhamento). Vários graus de reações de hifema e fibrina foram registrados como complicações precoces pós-operatórias. Phthisis bulbi foi desenvolvido em um caso durante o acompanhamento. A cirurgia de revisão da válvula Ahmed para glaucoma foi necessária em 4 casos. Conclusões: Os procedimentos cirúrgicos combinados que realizamos são seguros, eficazes e preferenciais, tanto em termos de controle da alta pressão intraocular quanto fornecimento de habilidades visuais razoáveis em pacientes com glaucoma neovascular complicado.

Glaucoma neovascular. A propósito de un caso / Neovascular glaucoma. A case report

Se presenta un paciente masculino de 60 años de edad, con antecedentes de padecer diabetes mellitus tipo II complicada con retinopatía diabética, así como glaucoma neovascular de tórpida evolución en el ojo izquierdo. Acude a consulta de glaucoma en el Centro Oftalmológico del Hospital Universitario Clínico- Quirúrgico «Arnaldo Milián Castro» de Villa Clara por presentar visión borrosa y molestias oculares en su ojo derecho. Al examen oftalmológico de dicho ojo se observa: disminución de la visión, sangramiento activo proveniente de vaso iridiano, edema corneal, rubeosis iridiana, hipertensión ocular y al fondo de ojo retinopatía diabética; se realizan complementarios hemáticos que muestran cifras de glicemia elevada (20 mmol/l). Se plantea el diagnóstico de glaucoma neovascular del ojo derecho en el curso de una diabetes mellitus tipo II descompensada. Se le indica tratamiento médico - quirúrgico y se logra una evolución favorable.

We present a 60-year-old male patient with a history of type II diabetes mellitus complicated by diabetic retinopathy, as well as neovascular glaucoma of torpid evolution in his left eye. He came to the glaucoma consultation in the Ophthalmological Center at "Arnaldo Milián Castro" Clinical and Surgical University Hospital in Villa Clara due to blurred vision and ocular discomfort in his right eye. Decreased vision, active bleeding from the iris vessel, corneal edema, iris rubeosis, ocular hypertension was observed in such eye at ophthalmological examination and diabetic retinopathy at eye fundus; blood tests were performed showing elevated glycemia figures (20 mmol /l). The diagnosis of neovascular glaucoma of the right eye is stated in the course of a decompensated type II diabetes mellitus. Medical and surgical treatment is indicated and a favourable evolution is achieved.

Deslocamento espontâneo do núcleo do cristalino para câmara anterior / Spontaneous displacement of the lens nucleus into the anterior chamber

RESUMO Ao longo da vida, o cristalino produz novas fibras dispostas de forma concêntrica, que aumentam seu diâmetro anteroposterior e peso, tornando seu núcleo mais compacto e endurecido. A catarata hipermadura é uma forma de progressão avançada dessa proliferação de fibras, que pode desencadear uma variedade de complicações. A ruptura espontânea da cápsula anterior do cristalino, evoluindo com deslocamento anterior do núcleo, é uma complicação rara e com poucos casos publicados na literatura. Descrevemos o caso de uma paciente do sexo feminino, 68 anos, que apresentou ruptura espontânea da cápsula anterior do cristalino com deslocamento anterior do núcleo em olho esquerdo sem histórico de trauma ocular. A paciente foi submetida à facoemulsificação do cristalino e ao controle da pressão intraocular, evoluindo com melhora do quadro clínico.

ABSTRACT Throughout life, the lens produces new fibers arranged concentrically, which increase its anteroposterior diameter and weight, making its nucleus more compact and hardened. Hypermature cataract is an advanced stage of this fiber proliferation, which can trigger a variety of complications. Spontaneous rupture of the anterior lens capsule evolving with anterior displacement of the nucleus is a rare complication, with few cases published in the literature. We describe the case of a 68-year-old female patient, who presented spontaneous rupture of the anterior lens capsule with anterior displacement of the nucleus in the left eye, without a history of ocular trauma. The patient underwent phacoemulsification and clinical control of intraocular pressure, improving her condition.

Hipertensão ocular recorrente durante hemodiálise em paciente portador de glaucoma / Recurrent intraocular hypertension during hemodialysis in glaucoma patient

RESUMO A hipertensão ocular aguda durante a hemodiálise constitui evento raro e pode ser causa relevante de interrupção do tratamento dialítico devido à dor. Relata-se o caso de um paciente de 70 anos de idade, do sexo masculino, que apresentou quadros recorrentes de intensa dor ocular unilateral durante sessões dialíticas devido ao aumento de pressão intraocular. O paciente era portador de grave diminuição da acuidade visual no olho direito devido a glaucoma neovascular, controlado com medicação hipotensora tópica. Uma hora após o início da sessão dialítica, apresentou dor excruciante no olho direito, sendo necessário interromper o tratamento por diversas vezes. A dor somente era amenizada com uso de opioides por via endovenosa ou após cerca de 6 horas do procedimento. Injeção intraocular de drogas antiangiogênicas e acetazolamida por via oral, assim como tratamentos tradicionais para quadros agudos de hipertensão intraocular, como uso de hipotensor tópico e medicamentos hiperosmolares, foram insuficientes para o controle da dor. O problema se resolveu com ciclofotocoagulação transescleral realizada com laser diodo, com redução da pressão intraocular basal e controle da dor, o que permitiu a realização de sessões completas de hemodiálise. A base fisiopatológica desse evento incomum e suas opções terapêuticas são discutidas aqui.

ABSTRACT Acute ocular hypertension during hemodialysis is a rare event and may lead to interruption of dialytic therapy due to pain. A case of a 70-year-old male patient is reported, who presented recurrent intense unilateral ocular pain episodes during dialysis sessions for increased intraocular pressure. The patient presented with severely decreased visual acuity in the right eye due to neovascular glaucoma, which was controlled with topical hypotensive medication. One hour after initiating dialysis, he presented an excruciating pain on the right eye, which required interruption of treatment several times. Pain relief was possible only with intravenous opioids, or approximately 6 hours after dialysis. Intraocular injection of antiangiogenic drugs and per oris acetazolamide, as well as other traditional treatments for acute episodes of intraocular hypertension, such as topical antihypertensive agents and hyperosmotic medications, were not sufficient to control pain. The problem was solved with transscleral diode laser cyclophotocoagulation, which reduced baseline intraocular pressure and controlled pain, enabling complete hemodialysis sessions. The pathophysiological aspects and therapeutic options of this unusual condition are discussed.

Tratamento do olho cego doloroso por glaucoma neovascular com ciclofotocoagulação transescleral / Transescleral cyclophotocoagulation treatment for painful eye with glaucoma neovascular

Resumo Objetivo: Avaliar a efetividade e o perfil de segurança da ciclofotocoagulação transescleral padrão (CTCTE) e sua variação técnica denominada slow cooking (CTCTE SC) em pacientes com olho cego doloroso por glaucoma neovascular. Métodos: Pacientes foram submetidos a exame oftalmológico, graduando o nível da dor através de escala gráfica/numérica e divididos em dois grupos, um para tratamento com CTCTE e outro CTCTE SC. O acompanhamento foi realizado no primeiro, trigésimo e nonagésimo dias. Resultados: Dos 26 pacientes inclusos, 11 (42,3%) eram do sexo masculino. A idade média dos pacientes foi de 69 anos. Destes, 16 pacientes foram submetidos ao tratamento CTCTE e 10 pacientes a CTCTE SC. A pressão intraocular (PIO) teve média pré tratamento de 49 ± 23 mmHg no grupo CFCTE e medias no 1º, 30º e 90º dias pós-operatórios respectivamente: 32 ± 24 mmHg, 38 ± 18 mmHg, 43 ± 10 mmHg. No grupo submetido a técnica CFCTE SC a PIO prévia foi 54 ± 16 mmHg e médias no 1º, 30º e 90º dias pós-operatórios respectivamente: 38 ± 22 mmHg, 39 ± 10 mmHg , 44 ± 09 mmHg. A redução da dor foi efetiva em 88,4% pacientes. Durante o pós-operatório foi verificado hiperemia, quemose e hifema. Não foram observadas complicações graves. Conclusão: O tratamento do olho cego doloroso com ciclofotocoagulação transescleral com baixa carga foi um procedimento seguro e eficaz na resolução da dor, mas apresentou um baixo nível de redução da pressão intraocular em ambas técnicas usadas.

Abstract Objective: To evaluate the effectiveness and safety profile of standard transescleral cyclophotocoagulation (CTCTE) and its technical variation of slow cooking (CTCTE SC) in patients with neovascular glaucoma pain. Methods: Patients underwent ophthalmological examination, grading their pain level through a graphical / numerical scale and divided into two groups, one for treatment with CTCTE and another CTCTE SC. Follow-up was performed on the first, thirtieth and ninetieth days. Results: Of the 26 patients included, 11 (42.3%) were male. The average age of the patients was 69 years. Of these, 16 patients underwent CTCTE treatment and 10 patients underwent CTCTE SC. Intraocular pressure (IOP) had a mean pre-treatment of 49 ± 23 mmHg in the CFCTE group and medians at the 1st, 30th and 90th postoperative days respectively: 32 ± 24 mmHg, 38 ± 18 mmHg, 43 ± 10 mmHg. In the group submitted to the CFCTE SC technique, the previous IOP was 54 ± 16 mmHg and averages on the 1st, 30th and 90th postoperative days respectively: 38 ± 22 mmHg, 39 ± 10 mmHg, 44 ± 09 mmHg. Pain reduction was effective in 88.4% patients. During the postoperative period, hyperemia, chemosis and hyphema were observed. No serious complications were observed. Conclusion: Painful blind eye treatment with low load transscleral cyclophotocoagulation was a safe and effective procedure for pain resolution, but presented a low level of intraocular pressure reduction in both techniques used.

Glaucoma neovascular y atrofia esencial de iris / Neovascular glaucoma and essential iris atrophy

Los glaucomas secundarios son de difícil manejo, independientemente de las causas. Entre ellos, el glaucoma neovascular representa un reto para los oftalmólogos por las causas que lo producen y la gran pérdida visual que provoca. De igual manera, el síndrome iridocorneoendotelial es una enfermedad poco frecuente. El glaucoma ocurre aproximadamente en el 50 por ciento de los casos en dependencia del síndrome que predomine, mucho más grave en la atrofia esencial del iris. Presentamos un caso clínico de una paciente femenina de 58 años de edad en quien aparecen en cada ojo, de manera independiente, estos dos tipos de glaucomas secundarios(AU)

Secondary glaucomas are always difficult to manage, no matter what their causes might be. Among them, neovascular glaucomas pose a challenge to ophthalmologists, due to the factors bringing them about and the great visual loss they produce. On the other hand, iridocorneal endothelial syndrome is an uncommon condition. Glaucoma develops in about 50 percent of the cases, depending on the prevailing syndrome, and is much more severe in essential iris atrophy. A clinical case is presented of a 58-year-old female patient with these two types of secondary glaucoma, one type in each eye(AU)

Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion / Incidência de neovasos de segmento anterior durante o tratamento de edema macular secundário a oclusão da veia central da retina

ABSTRACT Purpose: To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with macular edema secondary to central retinal vein occlusion (CRVO). Methods: In this prospective, randomized, double-masked, sham-controlled study, 35 patients with macular edema following CRVO were randomized to intravitreal bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the first 6 months of the study. The primary outcome was the incidence rate of ASN at month 6. The secondary outcomes were the mean changes from baseline in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography over time to month 12. Results: ASN developed in 8 (22.86%) eyes, including 5 (62.50%) eyes in the sham group and 3 (37.50%) eyes in the IVTA group, during 12 months of fol low-up (p=0.009). BCVA differed significantly (p<0.05) among the groups only at month 1. CFT did not differ significantly (p<0.05) among the groups over 12 months. NVG required surgery and developed in one eye despite laser treatment. Conclusion: Early treatment with intravitreal antivascular endothelial growth factor therapy decreases the rates of ASN and NVG after CRVO.

RESUMO Objetivo: Analisar as taxas de incidência de neovascularização do segmento anterior (NSA) e de glaucoma neovascular (GNV), em pacientes com edema macular secundário a oclusão de veia central da retina (OVCR), em tratamento com injeções intravítreas de triamcinolona (IVTA) ou bevacizumab (IVB). Métodos: Neste estudo prospectivo, randomizado, duplo mascarado e sham controlado, 35 pacientes com edema macular secundário a OVCR foram randomizados para IVB, IVTA ou para o grupo controle (sham), durante os 6 primeiros meses do estudo. O desfecho primário foi a taxa de incidência de NSA no mês 6. Os desfechos secundários foram alterações médias da acuidade visual corrigida (BCVA) e espessura foveal central (EFC) ao exame de tomografia de coerência óptica, até o mês 12. Resultados: NSA ocorreu em oito (22,86%) olhos, cinco (62,50%) olhos no grupo sham e três (37,50%) olhos no grupo tratado com injeções intravítreas de Triamcinolona, Não houve nenhum caso com NSA no grupo tratado com bevacizumab durante 12 meses de acompanhamento (p=0,009). A BCVA apresentou diferença estatisticamente significante (p<0,05) entre os grupos, somente no mês 1. A EFC não apresentou diferenças estatisticamente significantes (p<0,05) entre os grupos ao longo dos 12 meses. GNV ocorreu em um olho apesar do tratamento com laser e este paciente necessitou de intervenção cirúrgica. Conclusão: O tratamento precoce com injeções intravítreas de Anti VEGF podem diminuir as taxas de neovascularização do segmento anterior e glaucoma neovascular após oclusão de veia central da retina.

Intravitreal injection of Lucentis combined with trabeculectomy and pan retinal photocoagulation for neovascular glaucoma / 实用医学杂志

Objective To investigate the clinical efficacy of intravitreal injection of Lucentis combined with pan retinal photocoagulation and trabeculectomy for neovascular glaucoma(NVG). Methods Seventeen eyes of 15 patients with NVG were treated by 0.5 mg Lucentis intravitreal injection first. Trabeculectomy was performed 7 days later and Pan retinal photocoagulation 2 weeks later. Iris,anterior chamber angle neovascularization,intraocu?lar pressure ,and visual acuity were observed in the following 6 months. Results Iris and anterior chamber angle neovascularization were completely regressed 7 days after the injection in 17 eyes. Six months after photocoagulation, 6 eyes had different degrees of improvement in visual acuity,10 eyes no change in visual acuity and 1 eye decreased from anterior index to immediate manual. There was significant difference in pre?treatment IOP and postoperative IOP( t = 12.75 ,10.26 ,9.73 ,10.77 ,P < 0.01 ). No serious complications were observed after intravitreal injec?tion and trabeculectomy. Conclusions Intravitreal injection of Lucentis could significantly accelerate the regres?sion of iris and anterior chamber angle neovascularization ,which could improve the successful rate of trabeculecto?my and pan retinal photocoagulation. Intravitreal injection of Lucentis combined with trabeculectomy and panretinal photocoagulation is safe and effective for NVG.

Risk factors associated with neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy / 中华眼底病杂志

Objective To investigate the risk factors associated with neovascular glaucoma (NVG) after pars plana vitrectomy (PPV) in eyes with proliferative diabetic retinopathy (PDR).Methods Retrospective study.One hundred and thirty-seven patients (137 eyes) with PDR who underwent PPV were recruited.There were 85 males and 52 females.The average age was (60.1 ± 8.8) years old.The duration of diabetes was (10.2 ± 3.6) years.There were 49 patients with ipsilateral carotid artery stenosis.Fifty-three eyes underwent intravitreal ranibizumab or conbercept injection before PPV.All eyes were treated with 23G standard three-port PPV.The average follow-up time after PPV was 11.5 months.Fundus fluorescein angiography (FFA) was conducted in postoperative 4-6 weeks to observe non-perfused retinal areas.Risk factors,such as ipsilateral carotid artery stenosis,the presence of non-perfusion in retina after PPV and the application of anti-vascular endothelial growth factor (VEGF) drugs before PPV,were identified by logistic regression.Results Twenty of 137 patients (14.6％) developed postoperative NVG after PPV.Ipsilateral carotid artery stenosis [odds ratio (OR) =5.048,95％ confidence interval (CI) 2.057-12.389,P=0.000] and the presence of non-perfusion in retina after PPV (OR=4.274,95％CI 1.426-12.809,P=0.009) were significant risk factors for postoperative NVG,while the application of anti-VEGF drugs was not (OR=1.426,95％CI 0.463-4.395,P=0.536).But the time from PPV to the onset of NVG varies significantly between the two groups of injection of anti-VEGF drugs or not (t=-4.370,P=0.000).Conclusions Risk factors associated with NVG after PPV in eyes with PDR included ipsilateral carotid artery stenosis and the presence of non-perfusion in retina after PPV.The application of anti-VEGF drugs before PPV can delay the onset of NVG in PDR eyes after vitrectomy.

Crioterapia panretinal como profilaxis del glaucoma neovascular en ancianos diabéticos operados de catarata / Panretinal cryotherapy as prophylaxis of the neovascular glaucoma in diabetic elderly undergoing cataract surgery

Se realizó un estudio de cohorte de 18 ancianos diabéticos, afectados por catarata y algún grado de retinopatía, asistidos en las respectivas consultas de Catarata y Retina del Centro Oftalmológico del Hospital General Docente "Dr. Juan Bruno Zayas Alfonso" de Santiago de Cuba, desde julio de 2012 hasta marzo de 2013, con vistas a determinar la utilidad de la crioterapia panretinal como profilaxis del glaucoma neovascular. En la casuística predominaron las mujeres (66,6 %) y la media de edades de 68,1 años en el sexo femenino; entre los antecedentes patológicos personales y familiares primó la diabetes mellitus (con 100,0 y 88,8 %, respectivamente) y el síntoma más común fue la disminución progresiva de la visión en el período preoperatorio y la mala visión nocturna en el posoperatorio. Después de extraer el cristalino opacificado, la visión resultó superior a 0,4 en 83,3 % de los integrantes de la serie, lo cual posibilitó recuperar su capacidad funcional y, por tanto, aumentar sustancialmente su calidad de vida al prevenir la aparición del glaucoma neovascular.

A cohort study of 18 diabetic elderly, affected by cataract and some degree of retinitis, assistted in the respective Cataract and Retina services of the Ophthalmological Center of "Dr. Juan Bruno Zayas Alfonso" Teaching General Hospital in Santiago de Cuba, was carried out from July, 2012 to March, 2013, aimed at determining the utility of panretinal cryotherapy as prophylaxis of the neovascular glaucoma. In the case material the women (66.6%) and the mean ages of 68.1 years in the female sex prevailed; among the personal and family pathological history, the diabetes mellitus prevailed (with 100.0 and 88.8%, respectively) and the most common symptom was the progressive decrease of vision in the preoperative period and the bad night vision in the postoperative period. After extracting the opaque lens, the vision was higher at 0.4 in 83.3% of the series members, which facilitated recovering its functional capacity and, therefore, their life quality increased substantially by preventing the emergence of neovascular glaucoma.

Glaucoma neovascular, complicación de la isquemia retiniana / Neovascular glaucoma, a retinal ischemia complication

Introducción: el glaucoma neovascular es un tipo de glaucoma secundario frecuente en los pacientes diabéticos, se produce por la formación de una membrana fibrovascular a nivel del ángulo camerular, como consecuencia de un estímulo angiogénico producido por enfermedades que generan isquemia ocular. Los pacientes con retinopatía diabética proliferativa pueden sufrir esta enfermedad de difícil tratamiento para el oftalmólogo, y que constituye una amenaza para la visión del paciente. Objetivo: revisar aspectos clínicos, patogenia, métodos para el diagnóstico y tratamiento terapéutico del glaucoma neovascular con vistas a prevenir o reducir la pérdida visual. Desarrollo: el glaucoma neovascular es una complicación de la diabetes mellitus y de otras enfermedades generales, que provoca una disminución importante de la visión, y en muchas ocasiones, ceguera. Las enfermedades oculares que con más frecuencia lo producen son la oclusión de la vena central de la retina, la retinopatía diabética proliferativa y el síndrome isquémico ocular, generando isquemia retiniana y coroidea con la consecuente formación de neovasos. Conclusiones: la educación al paciente diabético y el adecuado tratamiento terapéutico de la retinopatía diabética es importante para prevenir la aparición del glaucoma neovascular(AU)

Introduction: neovascular glaucoma is the type of secondary glaucoma common in diabetic patients; it is caused by the formation of fibrovascular membrane at the camerular angle as a result of angiogenic stimulus due to ocular ischemia-generating diseases. The proliferative diabetic retinopathy patients may suffer this difficult-to-treat disease that represents a threat to the vision of a patient. Objective: to review clinical aspects, pathogenenesis, diagnosis methods and treatment of the neovascular glaucoma with a view to preventing or reducing the vision loss. Development: neovascular glaucoma is a complication of diabetes mellitus and of other general diseases, which brings about significant reduction of vision and often blindness. The most frequent eye diseases responsible for this are central retinal vein occlusion, proliferative diabetic retinopathy and ocular ischemic syndrome, leading to retinal and choroid ischemia with resulting formation of neovessels. Conclusions: education aimed at diabetic patient and the adequate therapeutic treatment of the diabetic retinopathy is important to prevent the occurrence of neovascular glaucoma(AU)

Levels of aqueous and serum VEGF, TGF-β1 ,IL-6 in neovascular glaucoma eyes / 中华实验眼科杂志

Background Neovascular glaucoma (NVG) is a refractory disease characterized by neovascularization,and its pathogenesis mechanism is still unelucidated.Researches showed that muhicytokins and inflammatory factors are associated with neovascularization,however,the correlation of these factors with NVG worth attention.Objective This study was to detect the vescular endothelial growth factor (VEGF),transforming growth factor β1 (TGF-β1) and interleukin-6 (IL-6) levels in aqueous humor and plasma in NVG eyes and its significance.Methods A prospective cases-controlled study was performed under the approval of Ethic Committee of Shanghai East Hospital and informed consent of patients.Eight eyes of 8 NVG patients,10 eyes of 10 primary open angle glaucoma (POAG) patients and 10 eyes of age-related cataract (ARC) patients were entrolled in Shanghai East Hospital from May,2014 to March,2015.The periphery blood of 3-4 ml was collected from all the patients to prepare 0.3-0.4 ml serum,and 0.1-0.2 ml aqueous humor was collected during the surgery from each eye.The aqueous and serum levels of VEGF,TGF-β1 and IL-6 were measured by ELISA.Results The aqueous humor and plasma VEGF concentrations in NVG patients were (2 769.85 ± 390.88) pg/ml and (529.93 ± 95.20) pg/ml,respectively,which were higher than (208.12 ± 58.59) pg/ml and (219.28 ± 24.44) pg/ml in POAG patients as well as (158.88 ±12.35) pg/ml and (172.82±31.91)pg/ml in ARC patients,with significant differences among the three groups (aqueous:F=433.80,P＜0.01;plasma:F=103.84,P＜0.01).The levels of TGF-β1 in aqueous humor and plasma from NVG patients were (157.94±113.00)pg/ml and (3 895.78±2 318.00)pg/ml,showing significant increases in comparison with (54.48±35.58) pg/ml and (2 196.13±1 185.39) pg/ml in the POAG patients or (47.98±17.69) pg/ml and (1937.28±933.27) pg/ml in the ARC patients (aqueous:F =7.88,P＜0.01;plasma:F =4.18,P＜0.05).The concentration of IL-6 in aqueous humor and plasma were (234.87±41.64) pg/ml and (26.97±8.19) pg/ml from NVG patients,with considerable elavation in comparison with (38.97± 19.06)pg/ml and (19.54±5.11)pg/ml in the POAG patients or (29.48±14.61) pg/ml and (18.50±3.57) pg/ml in the ARC patients (aqueous:F =166.27,P＜0.01;plasma:F=5.59,P＜0.05).Conclusions The aqueous and plasma VEGF,TGF-β1 and IL-6 are considerably higher in NVG patients than those in POAG patients and ARC patients,suggesting that these cytokines participate in the pathogenesis and development of the NVG and probably are treating target of NVG.

Detection and analysis of platelet-derived growth factor-c and vascular endothelial growth factor in ocular aqueous humor with neovascular glaucoma / 中华实验眼科杂志

Background Neovascular glaucoma (NVG) is a serious eye disease with a variety of causes.It results from the secretion of growth factors by hypoxic retinal tissue,such as vascular endothelial growth factor (VEGF),but anti-VEGF treatment alone dose not completely inhibit neovascularization.Our previous study found that platelet-derived growth factor-c (PDGF-C) is also an important factor in pathological angiogenesis.However,the role of PDGF-C in the development of NVG remains unknown.Objective This study was to quantitatively detect the levels of VEGF and PDGF-C in the aqueous humor of patients with NVG and provide a basis for the anti-angiogenesis therapy.Methods A prospective cohort study was carried out.Sixty-two eyes of 62 patients with advanced NVG and 11 control subjects with age related cataract were included in Xijing Hospital of the Fourth Military Medical University from January 2014 to August 2015.Ten of 62 NVG eyes received retinal photocoagulation and/or cryotherapy,and 16 eyes resulted from central retinal vein occlusion,20 eyes from diabetic retinopathy,5 eyes from postopeartion of retinal detachment,4 eyes from Eales disease and 7 eyes from unknown cause.Iris neovascularization of grade Ⅱ was found in 13 eyes,grade Ⅲ in 29 eyes and grade Ⅳ in 10 eyes.Aqueous humor specimen was collected for 0.1-0.2 ml during the surgery,and the contents of VEGF and PDGF-C in the aqueous humor were detected by ELISA assay.Written informed consent was obtained from each subject prior to any medical procedure.Results The VEGF and PDGF-C concentrations in the aqueous humor were (1 138.17±69.31) ng/L and (29.80±1.64) ng/L in the NVG group,respectively,which were significantly higher than (679.54±49.81) ng/L and (18.60±1.85)ng/L in the control subjects (t=20.95,20.49,both at P＜0.01).The VEGF and PDGF-C concentrations in aqueous humor were (1 095.99±52.71) ng/L and (28.55±0.94) ng/L in the retinal photocoagulation group,showing significantly decreases in comparison with (1 146.28±69.57) ng/L and (30.04± 1.64) ng/L in the untreatment group (t =-2.160,P =0.034;t =-2.760,P =0.008).The VEGF content in aqueous humor was positively correlated with PDGF-C content in the patients with NVG (r=0.346,P=0.006).However,the aqueous levels of VEGF and PDGF-C were not significantly different among various primary disease groups and different iris neovascularitation gradings (all at P＞0.05).Conclusions Both VEGF and PDGF-C contents in the aqueous humour are considerably elevated in NVG patients.Retinal photocoagulation and/or cryotherapy can inhibit the release of VEGF and PDGF-C in the aqueous humor.PDGF-C may be a target for the treatment of NVG.

Clinical problems and thoughts on the treatment of neovascular glaucoma / 中华实验眼科杂志

Neovascular glaucoma (NVG) is a dreadful pathology and it will be rapid spontaneous evolution responsible for eventual visual loss in many cases,with poor therapeutic efficiency.The main challenges in clinical practice for the management of NVG are as follows:(1) What is the goal of NVG treatment,to decrease intraocular pressure (IOP) or to reserve visual function? (2) How to create an optimal condition or timing for the treatment of primary disease? (3)What is exactly the key of NVG treatment? Anti-vascular endothelial growth factor (VEGF) medication,anti-glaucoma surgery or pan-retinal photocoagulation (PRP) for strict control of clinical situations potentially responsible for retinal ischemia ? (4)How to set up a comprehensive management strategy for NVG? In this paper,we established a comprehensive treatment strategy for NVG,including a core aim for preserving visual function,a goal of completing PRP and the main methods of anti-VEGF injection and anti-glaucoma surgery in order to preserve visual status of NVG patients as much as possible.

Intravitreal Ranibizumab Injection Combined with Complex Trabeculectomy in Treatment of Neovascular Glaucoma / 医药导报

Objective To investigate the clinical efficacy of intravitreal ranibizumab injection combined with complex trabeculectomy in treatment of neovascular glaucoma. Methods Totally 38 patients(38 eyes) of neovascular glaucoma were divided into two groups of 19 cases in each randomly. Patients in treatment group were treateded with complex trabeculectomy after intravitreal injection 0. 05 mL ( 0.5 mg ) ranibizumab 4 - 7 days. Patients in control group were treateded with cyclocryotherapy. Visual acuity, intraocular pressure, iris neovascularization and complications were observed. Results The average intraocular pressure of preoperation and postoperation 1 month in treatment group were (6.5±1.7) kPa and (2.1±1.2) kPa.The difference of intraocular pressure before and after operation was significant. The average preoperative and postoperative intraocular pressure in control group were (6.7±1.9) kPa and (2.5±1.2) kPa . The postoprative intraocular pressure of treatment group was lower than that of control group, the difference was statistically significant( P< 0.05). Visual acuity and operative reaction after operation in treatment group were superior to those in control group. Conclusion Intravitreal injection of ranibizumab combined with complex trabeculectomy in treatment of neovascular glaucoma is safe and effective and worth in clinical application.

Ciclofotocoagulación transescleral de contacto, una opción válida en el tratamiento del glaucoma neovascular / Contact transscleral cyclophotocoagulation, a valuable option for treatment of the neovascular glaucoma

Objetivo: describir los resultados de la ciclofotocoagulación tranescleral de contacto como opción de tratamiento en el glaucoma neovascular. Métodos: se realizó un estudio descriptivo, longitudinal prospectivo, en 100 pacientes con glaucoma neovascular atendidos en la Consulta Provincial de Glaucoma de la provincia de Pinar del Río, que cumplían con las indicaciones de la ciclofotocoagulación transescleral con láser. Resultados: el 69 por ciento de los pacientes tratados se encontraron entre los 61 y 80 años de edad. Hubo un predominio del sexo masculino. La agudeza visual se mantuvo estable posterior al tratamiento y hubo una reducción de la presión intraocular en el 91 por ciento de los casos. En el 62 por ciento se reportaron cifras inferiores a los 21 mmHg a los 3 meses posoperatorio; en el 89 por ciento de los pacientes se logró alivio del dolor y en el 75 por ciento hubo regresión de los neovasos. Conclusiones: la ciclofotocoagulación transescleral de contacto proporciona una reducción de la presión intraocular con alivio del dolor y regresión de los neovasos en los pacientes con glaucoma neovascular, y no se produce variación de la agudeza visual(AU)

Objective: to describe the results of contact transscleral cyclophotocoagulation as therapeutical alternative in the neovascular glaucoma. Methods: prospective, longitudinal and descriptive study of one hundred patients with neovascular glaucoma, who had been seen at the provincial glaucoma service of Pinar del Rio province and met the criteria for transscleral cyclophotocoagulation using laser. Results: sixty nine percent of treated patients were 61-80 years old. Males predominated. Visual acuity remained stable after treatment and the intraocular pressure lowered in 91 percent of cases. Sixty two percent reported figures lower than 231 mmHg three months after surgery, 89 percent of patients relieved their pain and the regression of neovessels occurred in 75 percent of cases. Conclusions: contact transscleral cyclophotocoagulation achieves the reduction of the intraocular pressure with pain relief and regression of neovessels in patients with neovascular glaucoma; the visual acuity does not change(AU)

Intravitreal ranibizumab as adjuvant treatment for neovascular glaucoma

The purpose of this study was to describe a prospective case series of 5 eyes treated with intravitreal ranibizumab injection for neovascular glaucoma (NVG). Five patients with clinically uncontrolled NVG secondary to proliferative diabetic retinopathy (4 patients) and central retinal vein occlusion (1 patient), non-responsive to maximal tolerable medication and panretinal photocoagulation, received intravitreal ranibizumab injection (0.5 mg). Patients were seen at 1st, 3rd and 7th day after the ranibizumab injection and when it was necessary. Success was defined as intraocular pressure (IOP) 21, despite maximal tolerable medication, underwent trabeculectomy with 0.5mg/ml mitomycin C (MMC) for 1 minute. Failure was defined as IOP > 21 mmHg, phthisis bulbi, loss of light perception or additional glaucoma surgery. The primary outcome was 6-month IOP control. Mean IOP before the ranibizumab injection was 37 mmHg (7 mmHg SD). Two out of five eyes underwent only ranibizumab injection, having an IOP control after the procedure. Three patients were submitted to trabeculectomy with MMC on the 7th day after the injection. At 6-month follow-up, the mean IOP was 12mmHg (3 mmHg SD). All eyes showed regression of rubeosis iridis and IOP control. Visual acuity improved in 2 eyes worsened in 1 eye, and remained stable in 2 eyes. These data suggest that intravitreal ranibizumab injection may be a useful tool in the treatment of NVG.

O objetivo deste estudo foi descrever uma série de casos prospectivos de 5 olhos tratados com ranibizumabe intravítreo para glaucoma neovascular (GNV). Cinco pacientes com GNV refratário, secundário a retinopatia diabética proliferativa (4 pacientes) e oclusão de veia central da retina (1 paciente), não responsivos a terapia medicamentosa máxima tolerada e panfotocoagulação da retina, receberam ranibizumabe intravítreo (0,5 mg). Os pacientes foram vistos no 1º, 3º e 7º dia após a aplicação e conforme necessário. O sucesso foi definido como pressão intraocular (PIO) d"21 mmHg, com ou sem uso de medicação antiglaucomatosa. Aqueles com PIO > 21 mmHg, apesar da medicação máxima tolerada, foram submetidos à trabeculectomia com mitomicina C (MMC) 0,5mg/mL por 1 minuto. Falência foi definida como PIO > 21 mmHg, phthisis bulbi, perda da percepção de luz ou necessidade de cirurgia antiglaucomatosa adicional. O resultado primário avaliado foi o controle da PIO após 6 meses do procedimento. A PIO média antes da injeção era de 37 mmHg (DP=7 mmHg). Dois pacientes foram submetidos somente a injeção intravítrea de ranibizumabe, obtendo controle da PIO após o procedimento. Três pacientes foram submetidos à trabeculectomia com MMC no 7º dia após a injeção. Após 6 meses de seguimento, a PIO média era de 12 mmHg (DP=3 mmHg). Todos os olhos mostraram regressão da rubeosis iriana e controle da PIO. A acuidade visual melhorou em 2 olhos, piorou em 1 olho e permaneceu estável em 2 olhos. Estas informações sugerem que a injeção intravítrea de ranibizumabe pode ser uma ferramenta útil no tratamento do GNV.

Clinical characteristics of neovascular glaucoma secondary to central retinal vein occlusion and diabetic retinopathy / 中华实验眼科杂志

Background Neovascular glaucoma (NVG) is a serious ocular disease which may cause blindness.The primary pathogenesis of NVG is ischemic retinopathy derived by central retinal vein occlusion (CRVO) and diabetic retinopathy (DR).Clinical characteristics of NVG are variable based on the difference of primary diseases,such as CRVO and DR.However,there is a few studies regarding the diffcrcnces of NVG initiated by CRVO and DR.Objective This study was to compare the clinical characteristics in NVG patients secondary to CRVO and DR.Methods A series case observational study was carried out in Hiserve Hospital of Qingdao University from January 2009 to June 2012.Twenty-nine eyes of 27 patients with NVG caused by CRVO (10 eyes of 10 patients) and DR (19 eyes of 17 patients) were included.The history of underlying diseases,course of NVG,intraocular pressure(IOP),fundus findings and complications after treatment were analyzed and compared between the CRVO-derived NVG and DR-derived NVG.All patients underwent panretinal photocoagulation,improving microcirculation therapy,anti-glaucoma (drug or surgery) and causative disease treatment,and some of them received vitrectomy or/and cataract surgery.Two eyes from each group received intravitreal injection of ranibizumab.The follow-up time in both groups was (14.00±10.13) months and (17.89±12.52) months,respectively.Results The median time of underlying disease was 3.3 months (2 weeks to 6 months) in the CRVO patients and 11.1 months (4 to 36 mouths) in the DR patients,with a significant difference between them (Z =-2.40,P＜0.05).CRVO-derived NVG progress was much faster than that of DR-derived NVG.The number of the eyes with visual acuity improvement after treatment was 2 in the CRVO-derived NVG and 15 in the DR-derived NVG;while the number of the eyes with unchanged or worse visual acuity was 8 and 4 in the CRVO-derived NVG eyes and the DR-derived NVG eyes (x2 =9.38,P＜0.01).The difference of IOP in pre-and post-treatment was (37.00±9.91)mmHg in the CRVOderived NVG eyes and (8.92±12.05)mmHg in the DR-derived NVG eyes,showing a significant difference between them (t =6.30,P＜0.01).In the CRVO-derived NVG eyes,optic disc edema,retinal hemorrhage,and vein dilatation were seen in 6 eyes,and mild optic disc edema and retinal hemorrhage were observed in 4 eyes.After treatment,fundus could not be seen in 4 eyes,in other 2 eyes optic disc and retinal laser spots were unclearly observed.In addition,pale optic disc and retinal vessel occlusion appeared in 2 eyes,and silver wire-like arteries exhibited in 2 eyes.In pre-treated DR-derived NVG eyes,fundus could not be seen in 8 eyes and Ⅲ-Ⅳv stages of DR findings appeared in 11 eyes.After treatment,retinopathy was stabilized in 16 eyes of 15 cases.Advanced retinopathy(V-Ⅵ stages of DR findings) was revealed in 3 eyes of 3 cases.The incidence of the complication after treatment was 100.0％ in the CRVO-derived NVG eyes and 21.1％ in the DR-derived NVG eyes (x2=5.18,P＜0.05).Conclusions The clinical characteristics of NVG secondary to CRVO and DR are variable,an appropriate treatment option should be selected according to different features of NVG.

The research of erythropoietin level in aqueous humor of patients with glaucoma / 中国医师进修杂志

Objective To evaluate the difference of the level of erythropoietin (EPO) in primary open-angle glaucoma (POAG),pseudo exfoliative glaucoma (PXFG),and neovascular glaucoma (NVG).Methods One hundred glaucoma patients and 30 single cataract patients (control group) without other ocular region disease and systemic disease were enrolled in this study.In glaucoma patients,POAG was 40 patients (POAG group),PXFG was 30 patients (PXFG group),NVG was 30 patients (NVG group).The level of EPO in aqueous humor was measured by double antibody sandwich enzyme-linked immunosorbent assay.Results The level of EPO in POAG group,PXFG group,NVG group,control group was (19.1 ±5.6),(18.8 ± 6.5),(142.7 ± 20.6),(0.9 ± 0.5) U/L.The level of EPO in POAG group,PXFG group,NVG group was significantly higher than that in control group,the level of EPO in NVG group was significantly higher than that in POAG group and PXFG group (P＜ 0.01).But the level of EPO between POAG group and PXFG group had no significant difference (P ＞ 0.05).The level of EPO in PXFG group with intraocular pressure control patients was lower than that in POAG group with intraocular pressure control patients [(14.6 ± 1.4) U/L vs.(18.5 ± 6.2) U/L],the level of EPO in PXFG group with intraocular pressure nocontrol patients was higher than that in POAG group with intraocular pressure no-control patients [(28.5 ±10.7) U/L vs.(19.2 ± 6.4) U/L],there was significant difference (P ＜ 0.05).In PXFG group,the level of EPO had positive relationship with intraocular pressure (P ＜ 0.05).The level of EPO in NVG group with intraocular pressure control and no-control patients was higher than that in POAG group and PXFG group with intraocular pressure control and no-control patients,there was significant difference (P ＜ 0.05).Single factor analysis showed that intraocular pressure,type of glaucoma had correlation with the level of EPO (P ＜0.01).Multiple factors analysis showed that type of glaucoma was the main effective factor of the level of EPO (P ＜ 0.01).Conclusions The level of EPO in POAG,PXFG and NVG patients is higher than that in single cataract patients.The associativity between the level of EPO and intraocular pressure in PXFG patients is higher than that in POAG and NVG patients.